Chest:体重不足的囊性纤维化患者肺移植后的生存率可以接受

2020-01-18 xiangting MedSci原创

BMI<17kg/m2的CF受者移植后生存率与其他常见的移植队列相当。BMI<17kg/m2作为CF人群的单一危险因素,不应被视为LTx的绝对禁忌症。

在美国(US)的大多数中心,体重指数(BMI)降低是肺移植(LTx)的绝对禁忌症。这项研究目标是相对于正常体重的囊性纤维化(CF)受者和其他常见的移植患者队列,量化美国中重度体重不足(BMI<17 kg/m2)的CF患者LTx后的生存率。

使用器官共享联合网络(UNOS)数据(20056月至201511月移植),计算出所有CF、慢性阻塞性肺病(COPD)、特发性肺纤维化(IPF)以及低体重和正常体重CF亚组的移植后中位生存期Kaplan-Meier估算值。按移植中心分层的Cox回归模型评估了与COPD受者相比(对照),BMI<17kg/m2 CF受者的移植后死亡风险。

CFCOPDIPF的中位移植后生存期[95CI]分别为7.9[7.28.6]5.9[5.66.2]5.5[5.25.8]。尽管与BMI≥17kg/m2CF受者相比,BMI<17kg/m2 CF受者移植后生存率有绝对值下降(7.0[4.57.9] vs.8.2[7.39.0]),Cox模型没有发现死亡风险升高(校正后HR 1.09 [0.901.32]p=0.38)。BMI<17kg/m2 CF受者与所有BMIsCOPD受者移植后死亡率没有差异(校正后HR 1.04 [0.861.25]p=0.71)。

BMI<17kg/m2CF受者移植后生存率与其他常见的移植队列相当。BMI<17kg/m2作为CF人群的单一危险因素,不应被视为LTx的绝对禁忌症。

原始出处:

Kathleen J. Ramos. UNDERWEIGHT PATIENTS WITH CYSTIC FIBROSIS HAVE ACCEPTABLE SURVIVAL AFTER LUNG TRANSPLANTATION: A UNOS REGISTRY STUDY. Chest. 17 January 2020.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2051495, encodeId=ed7b2051495c5, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Tue Jan 21 11:24:00 CST 2020, time=2020-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1929606, encodeId=31371929606eb, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Fri May 08 23:24:00 CST 2020, time=2020-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2006173, encodeId=88da20061e3f4, content=<a href='/topic/show?id=a5c54038142' target=_blank style='color:#2F92EE;'>#囊性纤维化患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40381, encryptionId=a5c54038142, topicName=囊性纤维化患者)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/17F844FBE270B8196CB4C53EC9493C57/100, createdBy=9d712500079, createdName=ms5906905816781247, createdTime=Wed Dec 02 13:24:00 CST 2020, time=2020-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1675924, encodeId=def016e59240c, content=<a href='/topic/show?id=7395403e580' target=_blank style='color:#2F92EE;'>#囊性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40375, encryptionId=7395403e580, topicName=囊性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=926927300775, createdName=wolongzxh, createdTime=Sun Dec 06 16:24:00 CST 2020, time=2020-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256742, encodeId=7f0c1256e4256, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Mon Jan 20 02:24:00 CST 2020, time=2020-01-20, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2051495, encodeId=ed7b2051495c5, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Tue Jan 21 11:24:00 CST 2020, time=2020-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1929606, encodeId=31371929606eb, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Fri May 08 23:24:00 CST 2020, time=2020-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2006173, encodeId=88da20061e3f4, content=<a href='/topic/show?id=a5c54038142' target=_blank style='color:#2F92EE;'>#囊性纤维化患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40381, encryptionId=a5c54038142, topicName=囊性纤维化患者)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/17F844FBE270B8196CB4C53EC9493C57/100, createdBy=9d712500079, createdName=ms5906905816781247, createdTime=Wed Dec 02 13:24:00 CST 2020, time=2020-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1675924, encodeId=def016e59240c, content=<a href='/topic/show?id=7395403e580' target=_blank style='color:#2F92EE;'>#囊性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40375, encryptionId=7395403e580, topicName=囊性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=926927300775, createdName=wolongzxh, createdTime=Sun Dec 06 16:24:00 CST 2020, time=2020-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256742, encodeId=7f0c1256e4256, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Mon Jan 20 02:24:00 CST 2020, time=2020-01-20, status=1, ipAttribution=)]
    2020-05-08 Smile2680
  3. [GetPortalCommentsPageByObjectIdResponse(id=2051495, encodeId=ed7b2051495c5, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Tue Jan 21 11:24:00 CST 2020, time=2020-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1929606, encodeId=31371929606eb, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Fri May 08 23:24:00 CST 2020, time=2020-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2006173, encodeId=88da20061e3f4, content=<a href='/topic/show?id=a5c54038142' target=_blank style='color:#2F92EE;'>#囊性纤维化患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40381, encryptionId=a5c54038142, topicName=囊性纤维化患者)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/17F844FBE270B8196CB4C53EC9493C57/100, createdBy=9d712500079, createdName=ms5906905816781247, createdTime=Wed Dec 02 13:24:00 CST 2020, time=2020-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1675924, encodeId=def016e59240c, content=<a href='/topic/show?id=7395403e580' target=_blank style='color:#2F92EE;'>#囊性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40375, encryptionId=7395403e580, topicName=囊性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=926927300775, createdName=wolongzxh, createdTime=Sun Dec 06 16:24:00 CST 2020, time=2020-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256742, encodeId=7f0c1256e4256, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Mon Jan 20 02:24:00 CST 2020, time=2020-01-20, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2051495, encodeId=ed7b2051495c5, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Tue Jan 21 11:24:00 CST 2020, time=2020-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1929606, encodeId=31371929606eb, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Fri May 08 23:24:00 CST 2020, time=2020-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2006173, encodeId=88da20061e3f4, content=<a href='/topic/show?id=a5c54038142' target=_blank style='color:#2F92EE;'>#囊性纤维化患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40381, encryptionId=a5c54038142, topicName=囊性纤维化患者)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/17F844FBE270B8196CB4C53EC9493C57/100, createdBy=9d712500079, createdName=ms5906905816781247, createdTime=Wed Dec 02 13:24:00 CST 2020, time=2020-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1675924, encodeId=def016e59240c, content=<a href='/topic/show?id=7395403e580' target=_blank style='color:#2F92EE;'>#囊性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40375, encryptionId=7395403e580, topicName=囊性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=926927300775, createdName=wolongzxh, createdTime=Sun Dec 06 16:24:00 CST 2020, time=2020-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256742, encodeId=7f0c1256e4256, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Mon Jan 20 02:24:00 CST 2020, time=2020-01-20, status=1, ipAttribution=)]
    2020-12-06 wolongzxh
  5. [GetPortalCommentsPageByObjectIdResponse(id=2051495, encodeId=ed7b2051495c5, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Tue Jan 21 11:24:00 CST 2020, time=2020-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1929606, encodeId=31371929606eb, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Fri May 08 23:24:00 CST 2020, time=2020-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2006173, encodeId=88da20061e3f4, content=<a href='/topic/show?id=a5c54038142' target=_blank style='color:#2F92EE;'>#囊性纤维化患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40381, encryptionId=a5c54038142, topicName=囊性纤维化患者)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/17F844FBE270B8196CB4C53EC9493C57/100, createdBy=9d712500079, createdName=ms5906905816781247, createdTime=Wed Dec 02 13:24:00 CST 2020, time=2020-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1675924, encodeId=def016e59240c, content=<a href='/topic/show?id=7395403e580' target=_blank style='color:#2F92EE;'>#囊性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40375, encryptionId=7395403e580, topicName=囊性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=926927300775, createdName=wolongzxh, createdTime=Sun Dec 06 16:24:00 CST 2020, time=2020-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256742, encodeId=7f0c1256e4256, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Mon Jan 20 02:24:00 CST 2020, time=2020-01-20, status=1, ipAttribution=)]

相关资讯

欧盟扩大了Vertex的囊性纤维化药物Kalydeco的应用范围,批准用于婴儿的治疗

欧洲监管机构已批准扩大Vertex的囊性纤维化(CF)药物Kalydeco(ivacaftor)的治疗范围。此次批准允许该药物用于6个月至12个月、体重5kg及以上的婴儿,其囊性纤维化跨膜电导调节剂(CFTR)中至少存在9种突变中的一个。

Aridis柠檬酸镓吸入剂AR-501治疗囊性纤维化肺部感染,喜获EMA孤儿药物指定

Aridis Pharmaceuticals宣布,欧洲药品管理局(EMA)已为其柠檬酸镓吸入剂AR-501治疗囊性纤维化患者的肺部感染,授予Orphan Drug Designation。今年6月,Aridis还收到美国食品和药物管理局(FDA)针对AR-501的Orphan药物指定。

Lancet:3联疗法治疗F508del纯合子囊性纤维化

研究认为,Elexacaftor、Tezacaftor+Ivacaftor对囊性纤维化F508del纯合子突变患者具有较好的治疗效果

**名患者参加勃林格殷格翰的钠通道抑制剂治疗囊性纤维化的II期临床试验

针对成人和青少年的囊性纤维化,勃林格殷格翰(Boehringer Ingelheim)开发和生产的吸入上皮钠通道(ENaC)抑制剂的II期试验已招募了第一名患者,进行每天两次的治疗。该试验将不同剂量的化合物(BI 1265162)与安慰剂对比如何影响肺功能。

NEJM:Elexacaftor-Tezacaftor-Ivacaftor治疗PHE508DEL型囊性纤维化

研究认为,Elexacaftor-Tezacaftor-Ivacaftor对PHE508DEL-最小功能基因型囊性纤维化患者具有较好的治疗效果

FDA批准Trikafta用于治疗CFTR基因突变的囊性纤维化患者

美国食品和药物管理局(FDA)已批准Vertex的Trikafta(elexacaftor / tezacaftor / ivacaftor和ivacaftor)用于治疗囊性纤维化(CF)。该公司宣布批准将该药用于治疗12岁及以上,囊性纤维化跨膜电导调节剂(CFTR)基因中至少有一个F508del突变的患者。